Clinical Trial Update: The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema [Phase 2]

View source ↗

Summary

The TIME-2 Phase 2 trial of AKB-9778, a Tie-2 activator, for diabetic macular edema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• AKB-9778

Snippet

Sponsor: Aerpio Therapeutics | Conditions: Diabetic Macular Edema (DME) | Phase 2 | Status: COMPLETED